2021
Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study
Ramsey CM, Lynch KG, Thase ME, Gelernter J, Kranzler HR, Pyne JM, Shih MC, Stone A, Committee C, Oslin DW. Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. Journal Of Affective Disorders 2021, 282: 1272-1277. PMID: 33601706, DOI: 10.1016/j.jad.2021.01.034.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMental Health Care studyGene-drug interactionsDepressive disorderPGx testingAD treatmentCare studiesHealth care studiesPrecision medicineContext of pharmacotherapyPrevalence of antidepressantsUtility of PGxPrescribing practicesUS veteransPharmacogenetic testingAntidepressantsPatientsPrevious treatmentPrevalenceTreatmentDisordersPGxMedicineTest panelParticipants
2020
Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial
Oslin DW, Chapman S, Duvall SL, Gelernter J, Ingram E, Kranzler HR, Lehmann LS, Lynch JA, Lynch KG, Pyne JM, Shih MC, Stone A, Thase ME, Wray LO. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial. Contemporary Clinical Trials 2020, 101: 106247. PMID: 33316457, DOI: 10.1016/j.cct.2020.106247.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPGx test resultsRandomized clinical trialsClinical trialsPGx testingHealth care cost implicationsUtility of PGxRoutine clinical carePragmatic randomized clinical trialsEpisode of careHealth care trialsPrecision medicineHealth care providersPrecision medicine approachPatient care costsImplementation science methodsCare trialsMedication selectionPsychotropic medicationsProvider educationDepressive disorderPatient outcomesPharmacogenetic testingCare providersClinical care